Healthstream (HSTM) Research & Development (2010 - 2026)

Healthstream (HSTM) has reported Research & Development for 17 consecutive years, with $13.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 12.49% year-over-year to $13.6 million in Q2 2026; TTM through Jun 2026 was $54.1 million, a 10.37% increase from a year earlier, with the FY2025 full-year figure at $51.0 million, up 4.28% from the prior year.
• Research & Development was $13.6 million for Q2 2026 at Healthstream, roughly flat from $13.6 million in the prior quarter.
• Over five years, Research & Development peaked at $14.8 million in Q4 2025 and troughed at $10.4 million in Q1 2022.
• A 5-year average of $12.1 million and a median of $12.1 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development fell 1.77% in 2023 and gained 16.35% in 2025, its largest moves.
• Over 5 years, Research & Development stood at $11.6 million in 2022, then slipped by 1.77% to $11.4 million in 2023, then increased by 11.06% to $12.7 million in 2024, then grew by 16.35% to $14.8 million in 2025, then retreated by 7.96% to $13.6 million in 2026.
• The last three Research & Development figures came in at $13.6 million (Q2 2026), $13.6 million (Q1 2026), and $14.8 million (Q4 2025), per Business Quant data.